Iqvia Holdings Inc Revenue Growth Rates (IQV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Iqvia Holdings Inc   (NYSE: IQV)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

IQV's Revenue Growth by Quarter and Year

Iqvia Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IQV/growth
https://api.csimarket.com/api/v1/companies/IQV/fundamentals
https://api.csimarket.com/api/v1/companies/IQV/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IQV Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 4,428.00
2nd Quarter June 4,368.00
1st Quarter March 4,151.00
FY 12,947.00

IQVs Annual Revenue
Iqvia Holdings Inc 's Revenue in the fiscal year 2025 $ 16,310.00 millions
Iqvia Holdings Inc 's Revenue in the fiscal year 2024 $ 15,405.00 millions
Iqvia Holdings Inc 's Revenue in the fiscal year 2023 $ 14,984.00 millions
Iqvia Holdings Inc 's Revenue in the fiscal year 2022 $ 14,410.00 millions
Iqvia Holdings Inc 's Revenue in the fiscal year 2021 $ 13,874.00 millions




IQV Revenue third quarter 2026 Y/Y Growth Comment
Iqvia Holdings Inc reported Revenue growth of 8% year on year in the third quarter 2026, to $ 4,428.00 millions, this is lower than Iqvia Holdings Inc 's recent average Revenue increase of 10.46%.

Looking into third quarter 2026 results within Medical Laboratories industry 18 other companies have achieved higher Revenue growth. While Iqvia Holdings Inc ' s Revenue increase of 8% ranks overall at the positon no. 1994 in the third quarter 2026.


IQV Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8 %
2nd Quarter June 8.74 %
1st Quarter March 8.41 %
FY   -

Financial Statements
Iqvia Holdings Inc 's third quarter 2026 Revenue $ 4,428.00 millions IQV's Income Statement
Iqvia Holdings Inc 's third quarter 2025 Revenue $ 4,100.00 millions Quarterly IQV's Income Statement


IQV Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1.37 %
2nd Quarter June 5.23 %
1st Quarter March -4.88 %
FY (Year on Year)   -


Back to IQV Growth rate Comparisons >> Back to IQV Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #19
Healthcare Sector #295
Overall #1994

Revenue Y/Y Growth Statistics
High Average Low
64.64 % 10.46 % -7.99 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #19
Healthcare Sector #295
Overall #1994
Revenue Y/Y Growth Statistics
High Average Low
64.64 % 10.46 % -7.99 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Iqvia Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
56.17 % 2.64 % -8.46 %
(Dec 31 2016)  


IQV's III. Quarter Q/Q Revenue Comment
Iqvia Holdings Inc achieved in the III. Quarter 2026 below company average Revenue growth of 1.37% quarter on quarter, to $ 4,428.00 millions.

Within Medical Laboratories industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Iqvia Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1605.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #13
Healthcare Sector #216
Overall #1605
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #13
Healthcare Sector #216
Overall #1605
Revenue Q/Q Growth Statistics
High Average Low
56.17 % 2.64 % -8.46 %
(Dec 31 2016)  


IQV's III. Quarter Q/Q Revenue Comment
Iqvia Holdings Inc achieved in the III. Quarter 2026 below company average Revenue growth of 1.37% quarter on quarter, to $ 4,428.00 millions.

Within Medical Laboratories industry 12 other companies have achieved higher Revenue quarter on quarter growth. While Iqvia Holdings Inc 's Revenue growth quarter on quarter, overall rank is 1605.


Iqvia Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 17,311.00
Y / Y Revenue Growth (TTM) 8.85 %
Year on Year Revenue Growth Overall Ranking # 1827
Seqeuential Revenue Change (TTM) 1.93 %
Seq. Revenue Growth (TTM) Overall Ranking # 1827


Cumulative Revenue growth Comment
Iqvia Holdings Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 8.85% year on year, to $ 17,311 millions if the fiscal year would have ended in Sep 30 2026.
Iqvia Holdings Inc 's trailing twelve months Revenue growth was higher than company's average 6.85% and higher than 8.17% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 1.93 % from $16983 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at6.85%.

In the Healthcare sector 324 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1827, from total ranking in previous quarter at 2242.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 325
Overall # 2222

Revenue TTM Y/Y Growth Statistics
High Average Low
56.72 %
 6.85 %
-56.53 %
(Sep 30 2017)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 359
S&P 500 # 2523
Cumulative Revenue growth Comment
Iqvia Holdings Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 8.85% year on year, to $ 17,311 millions if the fiscal year would have ended in Sep 30 2026.
Iqvia Holdings Inc 's trailing twelve months Revenue growth was higher than company's average 6.85% and higher than 8.17% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 1.93 % from $16983 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at6.85%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 1.93 % increase from $16983 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 324 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1827, from total ranking in previous quarter at 2242.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 23
Healthcare Sector # 325
Overall # 2222

Revenue TTM Y/Y Growth Statistics
High Average Low
56.72 %
6.85 %
-56.53 %
(Sep 30 2017)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 359
S&P 500 # 2523




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IQV's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions
Elanco Animal Health Incorporated11.26%$ 11.258 millions
Koru Medical Systems Inc 11.19%$ 11.194 millions
Elite Pharmaceuticals Inc 11.11%$ 11.113 millions
Pro dex Inc 10.96%$ 10.955 millions
Nrc Health10.95%$ 10.954 millions
Anika Therapeutics Inc 10.91%$ 10.912 millions


About Iqvia Holdings Inc Revenue Growth Rates (IQV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Iqvia Holdings Inc (CIK 1478242).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-067646
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Iqvia Holdings Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.